GSK 189,254

GSK-189,254 is a potent and selective H₃ histamine receptor inverse agonist developed by GlaxoSmithKline. It has subnanomolar affinity for the H₃ receptor (K_i = 0.2nM) and selectivity of over 10,000x for H₃ over other histamine receptor subtypes. Animal studies have shown it to possess not only stimulant and nootropic effects, but also analgesic action suggesting a role for H₃ receptors in pain processing in the spinal cord. GSK-189,254 and several other related drugs are currently being investigated as a treatment for Alzheimer's disease and other forms of dementia, as well as possible use in the treatment of conditions such as narcolepsy, or neuropathic pain which do not respond well to conventional analgesic drugs.